Pharmaceuticals News and Research

RSS

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.

19 Oct 2010

International investors take interest in Australia's biotechnology industry at ALSIS 2010

AusBiotech has kicked off its annual conference with a hugely successful Australasian Life Sciences Investment Summit 2010 in Melbourne today. The premier life science investment conference for Australia and the Asia-Pacific region attracted 150 investors from more than 100 organisations to hear 39 selected Australian biotechnology companies.

19 Oct 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

ShangPharma prices initial public offering of American depositary shares

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its initial public offering of American depositary shares ("ADSs") was priced at $15 per ADS.

19 Oct 2010

New clinical trial to treat brain cancer launched

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm together with immatics biotechnologies have launched the first clinical trial of a promising cancer vaccine to treat glioblastoma, one of the most common forms of brain cancer.

19 Oct 2010

OncoGenex announces public offering of common stock

OncoGenex Pharmaceuticals, Inc. today announced that it is commencing a public offering of its common stock and warrants to purchase shares of its common stock.

19 Oct 2010

Elorac acquires world-wide rights to Cidoxepin

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, is pleased to announce that it has acquired world-wide rights to the active agent Cidoxepin from Gideon Pharmaceuticals. Cidoxepin is the cis-isomer of the widely prescribed tricyclic compound doxepin.

19 Oct 2010

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.

19 Oct 2010

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Sequella, Inc., a clinical-stage company focused on commercializing novel drugs for treatment of life-threatening infectious diseases, announced it has signed an agreement with the Ludwig-Maximilians-University (LMU) of Munich to coordinate a European Union grant for Phase 2 clinical trials of SQ109 in adult pulmonary tuberculosis (TB) in seven sites in Africa.

18 Oct 2010

Diversified Agency Services acquires medical communications agency Excerpta Medica

Omnicom Group's Diversified Agency Services (DAS) has acquired Amsterdam-based medical communications agency Excerpta Medica www.excerptamedica.com from world-leading publisher Elsevier, a division of Reed Elsevier Group plc.

18 Oct 2010

Cmed debuts Timaeus 5 unified eClinical platform and Timaeus HotSpot regulatory-compliant eClinical suite

Cmed Technology, an eClinical technology provider, today unveiled two product previews at two major pharmaceutical conferences. It debuted Timaeus 5, Cmed's newest version of its unified eClinical platform to manage data from Study Design through Reporting. Timaeus 5 adds enhanced usability, extended operational capabilities, streamlined investigator and monitor interaction, and expanded reporting capabilities.

18 Oct 2010

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.

18 Oct 2010

Lannett announces launch of Fluphenazine HCl Tablets

Lannett Company, Inc., a manufacturer of generic pharmaceuticals, today announced that it has commenced shipping Fluphenazine HCl Tablets USP, the generic equivalent of Prolixin®, in 1 mg, 2.5 mg, 5 mg and 10 mg dosages. For the 12 months ended September 2010, Fluphenazine HCl Tablets USP, 1 mg, 2.5 mg, 5 mg, & 10 mg had U.S. sales of approximately $28 million at Average Wholesale Price.

18 Oct 2010

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes.

18 Oct 2010

79% of uninsured and unemployed unaware of free medicine programs

With nearly 15 million people still without jobs, programs that help patients receive their medicines either for free or at reduced cost are a godsend for many. Yet few take advantage of them.

18 Oct 2010

New Trident IWR platform launched at SCDM 2010 Conference

BioClinica, Inc., a leading global provider of clinical trial management services, today announced the launch of its new IVR/IWR (interactive voice response/interactive web response) platform, Trident IWR, at the 2010 Society for Clinical Data Management Annual Conference (SCDM).

From Clario 18 Oct 2010

BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc. today announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important enrollment milestone triggers the first unblinded statistical analysis of cardiovascular events by the independent Data Monitoring Committee (DMC), which coincides with their fourth unblinded review of all adverse events.

18 Oct 2010

Emollient creams on eczemous skin likely to make condition worse

New research at the University of Bath suggests that using emollient creams to relieve the symptoms of eczema could actually make the condition worse.

18 Oct 2010

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.

18 Oct 2010

Fera Pharmaceuticals launches Garamycin Ophthalmic Ointment

Fera Pharmaceuticals announced the launch today of preservative free Garamycin (gentamicin sulfate) Ophthalmic Ointment USP.

18 Oct 2010

Pharmaceuticals News and Research

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

International investors take interest in Australia's biotechnology industry at ALSIS 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

ShangPharma prices initial public offering of American depositary shares

New clinical trial to treat brain cancer launched

OncoGenex announces public offering of common stock

Elorac acquires world-wide rights to Cidoxepin

Somaxon announces nonreceipt of Paragraph IV certification for generic Silenor ANDA

Sequella to develop SQ109 further with EDCTP, LMU, and TB experts in PanACEA

Diversified Agency Services acquires medical communications agency Excerpta Medica

Cmed debuts Timaeus 5 unified eClinical platform and Timaeus HotSpot regulatory-compliant eClinical suite

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Lannett announces launch of Fluphenazine HCl Tablets

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

79% of uninsured and unemployed unaware of free medicine programs

New Trident IWR platform launched at SCDM 2010 Conference

BioSante enrolls 2,500th woman in LibiGel Phase III cardiovascular and breast cancer safety study

Emollient creams on eczemous skin likely to make condition worse

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Fera Pharmaceuticals launches Garamycin Ophthalmic Ointment

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence